and scientific integrity.

Review Local Legislation: Review Lebanese laws related to pharmaceuticals, including Law No. 367 on the regulation of clinical trials. Understanding these laws will help in preparing the necessary documents for submission.

Identify Relevant Acts and Regulations: Apart from local laws, encompassing regulations related to data protection such as the Lebanese Personal Data Protection Law is vital to maintaining compliance throughout your clinical trial.

Documentation expectations at this stage include keeping track of all relevant guidelines and preparing a checklist that aligns with both MOH requirements and ICH-GCP standards. This preparation will facilitate a smoother review process later on.

Step 2: Dossier Preparation for Clinical Trial Application

The next step involves compiling a robust clinical trial application dossier. This dossier should encapsulate all pertinent information that the MOH requires for review. The following are critical components for your clinical trial application dossier:

• Clinical Trial Protocol: This document should detail the study design, objectives, methodology, statistical considerations, and ethical considerations. Ensure that your protocol follows the template recommended by the MOH and ICH.
• Informed Consent Forms: Prepare clear and comprehensible informed consent documents in accordance with ethical standards. The informed consent process is vital in ensuring participant understanding and voluntariness.
• Investigational Product Information: Supply comprehensive details regarding the investigational drug or device, including manufacturing details, formulation, and intended use.
• Research Team Qualifications: Include CVs of key research personnel, emphasizing their qualifications and previous experience in clinical trials.
• Safety Monitoring Plan: Create a safety monitoring plan that outlines how adverse events will be recorded and reported in compliance with pv pharmacovigilance standards.

All documents must be submitted in both English and Arabic, and it is advisable to maintain an up-to-date electronic version of the dossier to facilitate rapid modifications as needed.

Step 3: Submission to the Ministry of Public Health

Upon finalizing the clinical trial dossier, the next step is its submission to the MOH. Following proper submission protocols is crucial to expedite the review process:

• Choose the Correct Submission Channel: The Ministry allows both electronic and physical submissions. Ensure you are familiar with the requirements for the selected submission mode to avoid delays.
• Submission Fees: Confirm the amounts due for the processing of your application, which may vary based on the nature of the trial (e.g., Phase I, II, or III). Pay these fees promptly to avoid any processing hold-ups.
• Tracking Your Submission: Once submitted, use the MOH’s tracking system to monitor your application status. This proactive approach can assist in addressing any unforeseen issues quickly.

Thorough checks should be conducted to ensure all components of your application are complete and accurate. Incomplete applications are a common cause of delays and may result in additional requests for information from the MOH.

Step 4: Reviewing the Application and Addressing Queries

Once submitted, your application will undergo a rigorous review process. The MOH evaluates the ethical considerations, scientific validity, and regulatory compliance of your clinical trial. During this phase, it is essential to be prepared to respond to queries from the review committee efficiently:

• Understanding the Review Timeline: The typical review period by the MOH is approximately 3 months, but this may vary based on the complexity of the trial and other concurrent applications.
• Responding to Queries: It is common for the MOH to contact the sponsor for additional information or clarification. Maintaining open channels of communication and responding promptly is key to mitigating delays.
• Documenting Communications: Keep a detailed log of all communications with the MOH, including dates, content, and responses. This documentation can be essential for future regulatory audits.

Utilizing an organized document management system can enhance the efficiency of responding to the MOH’s requests and put the regulatory affairs team in a stronger position throughout the approval process.

Step 5: Ethics Committee Approval

Ethics committee approval is a crucial step in the clinical trial approval process in Lebanon. The MOH requires that all clinical trials receive ethical review prior to commencement. The following steps will guide the process of obtaining ethics committee approval:

• Identify the Appropriate Ethics Committee: Determine which research ethics committee is appropriate for your study’s domain, as some committees specialize in specific therapeutic areas.
• Submit Required Documents: Include all relevant documents from your application dossier, such as the clinical trial protocol and informed consent forms. Some ethics committees may also require additional documentation.
• Engage with the Committee: Be prepared to engage with the ethics committee during their review process. This may involve attending meetings to present your study and answer questions.
• Amend Protocol if Required: If the ethics committee suggests amendments to your protocol, it is essential to comply and resubmit the modified documents promptly.

Obtaining ethics committee approval may take between 1-3 months, depending on their meeting schedules and workload. Thorough preparation and addressing their concerns adequately will facilitate this process.

Step 6: Obtaining Authorization for Clinical Trial Commencement

Upon securing both MOH approval and ethics committee clearance, the next phase is the authorization for the commencement of your clinical trial. This step involves ensuring compliance with local legislation and preparing for the initiation of the study:

• Finalizing the Study Infrastructure: Ensure that all study sites are equipped and ready to carry out the trial as per the approved protocol. This includes training site staff on GCP and protocol adherence.
• Site Initiation Visits: Conduct site initiation visits to ensure that investigators and their teams understand their responsibilities and procedures associated with the trial.
• Pharmacovigilance Planning: Establish a comprehensive pharmacovigilance plan, including reporting adverse events in line with both local and international regulations.
• Monitoring Readiness: Prepare for trial monitoring by recruiting and training a qualified monitor familiar with the specific therapeutic areas and ICH-GCP requirements.

Documentation and data management processes must be meticulously organized at this stage to ensure that data collection aligns with the approved compliance standards throughout the trial duration.

Step 7: Conducting the Clinical Trial

The next step is the actual conduct of the clinical trial. At this stage, adhering to compliance, regulatory audit processes, and comprehensive data management systems are critical:

• Adherence to Protocol: All clinical trial activities must strictly follow the finalized protocol to ensure validity and consistency. Any deviations must be documented and justified in line with regulatory expectations.
• Ongoing Pharmacovigilance: Throughout the trial, continuous monitoring of participant safety is essential. Any adverse events must be recorded and reported in accordance with the established pharmacovigilance plan.
• Data Management Systems: Implement robust data management systems for collecting and analyzing trial data, ensuring the integrity and confidentiality of participant information.
• Periodic Reporting: Regular updates and reports should be provided to the MOH and ethics committee as required, detailing progress and any pertinent findings or issues encountered during the trial.

Fostering a culture of quality assurance and regulatory compliance during the execution of the clinical trial will facilitate smoother auditing processes, benefitting the overall integrity of the trial.

Step 8: Post-Approval Commitments and Reporting

Upon completion of the clinical trial, the final phase involves fulfilling post-approval commitments, documenting outcomes, and ensuring that all findings are reported as per regulatory requirements:

• Final Study Reports: Prepare comprehensive final study reports that outline all trial findings, methodologies, and analyses. These documents must uniformly represent data interpretations and adhere to regulatory formats.
• Submission of Safety Reports: Provide periodic safety updates to the MOH, detailing any significant findings that may impact the risk-benefit assessment of the investigational product.
• Retention of Study Documentation: Ensure retention of all clinical trial documents for a minimum duration as stipulated by the MOH and applicable regulations. This documentation may be required for future auditing and inspection.
• Implement Lessons Learned: Conduct a thorough analysis of the trial process upon completion. Identifying strengths and weaknesses will aid in enhancing future study designs and compliance strategies.

Maintaining organized records of all trial-related correspondence and submissions is critical during this phase, ensuring that the sponsors meet all obligations as outlined by the MOH and upholding compliance with global standards.